3,952 reports of this reaction
7.5% of all TICAGRELOR reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 3,952 FDA adverse event reports linking TICAGRELOR to DYSPNOEA. This represents approximately 7.5% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among TICAGRELOR users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 3,952 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 7.5% of all adverse event reports for TICAGRELOR, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.